Advertisement
ABT or MDT or SYK
Which Stock Would AI Choose? Abbott Laboratories (ABT) vs. Medtronic plc (MDT) vs. Stryker Corporation (SYK) Stock Comparison
Key Takeaways
- ABT has experienced notable year-to-date declines amid broader healthcare sector pressures, trading below recent analyst targets despite solid Q1 revenue of $11.16 billion and mid-single-digit growth guidance.
- MDT delivered its strongest annual revenue growth in a decade in fiscal 2026, with Q4 results beating estimates and supporting post-earnings share gains.
- SYK maintains relative stability compared with peers but remains down year-to-date and over the past year, reflecting mixed earnings momentum and valuation sensitivity.
- Business models overlap in medical technology, yet MDT shows stronger recent top-line execution while ABT and SYK face greater recent price pressure.
- Market sentiment favors companies with clear revenue catalysts, positioning MDT favorably in recent weeks relative to the group.
- Valuation metrics and earnings trends suggest differentiated risk-reward profiles across the three names in the current environment.
Introduction
This comparison examines ABT, MDT, and SYK, three established players in the medical technology and healthcare equipment sector. These stocks appeal to investors seeking exposure to innovation in diagnostics, cardiovascular devices, and surgical equipment. Traders monitoring relative performance, sector rotation, and earnings momentum may find the analysis useful for assessing positioning within a defensive yet growth-oriented industry. The review focuses on observable recent market activity, business fundamentals, and comparative factors without forward projections.
ABT Overview and Recent Performance
Abbott Laboratories operates across diagnostics, medical devices, nutrition, and established pharmaceuticals, with significant exposure to cardiovascular and diabetes care. In recent weeks, the stock has traded lower amid year-to-date declines exceeding 20 percent, influenced by sector-wide valuation adjustments and mixed sentiment around diagnostics demand. Q1 2026 revenue reached $11.16 billion, aligning with mid-single-digit organic growth expectations. Analyst price targets remain above current levels, yet price behavior reflects caution on near-term catalysts despite ongoing product innovation.
MDT Overview and Recent Performance
Medtronic plc develops and manufactures medical devices focused on cardiovascular, neuroscience, surgical, and diabetes management. The company reported fiscal 2026 revenue of $36.36 billion, marking its highest annual growth in ten years at 8.4 percent as reported. Q4 results in early June exceeded estimates on robust demand for heart devices, contributing to share gains in subsequent trading. In recent market activity, the stock has shown resilience near multi-week levels while navigating broader healthcare volatility.
SYK Overview and Recent Performance
Stryker Corporation specializes in orthopedic implants, surgical equipment, and neurotechnology products. The stock has declined year-to-date and over the trailing twelve months, with recent sessions reflecting modest volatility around earnings-related sentiment. Q1 2026 revenue grew modestly, though adjusted earnings per share missed consensus. In recent weeks, performance has been relatively contained compared with peers, supported by consistent analyst attention on long-term procedural volume trends.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of the platform’s extensive library of AI trading bots. Tickeron offers hundreds of AI Trading Bots that trade thousands of different tickers, yet only the best and most suitable for current market conditions earn placement in this section. Available bots display varied trading styles, strategies, timeframes, performance statistics, and ticker sets, with many demonstrating win rates and returns across different market regimes. Readers can explore the full range of options and backtested metrics directly on the site. Trending AI Robots
Head-to-Head Comparison
The three companies share exposure to elective procedures and hospital capital spending, yet differ in growth drivers. MDT has demonstrated stronger recent revenue expansion through portfolio execution, contrasting with ABT’s diagnostics sensitivity and SYK’s orthopedic focus. Valuation sensitivity appears higher for names with steeper recent drawdowns, while market sentiment has rewarded consistent top-line delivery. Risk factors include regulatory and reimbursement pressures common to the sector, with MDT showing comparatively steadier momentum in the latest period. Trade-offs center on balancing growth visibility against price stability.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings execution, and relative positioning in recent weeks, Tickeron’s AI assigns a probabilistic preference to MDT among the three. The company’s fiscal 2026 revenue growth and post-earnings response provide measurable support relative to peers facing more pronounced recent price pressure. This assessment remains probabilistic and tied to current data patterns rather than guarantees of future outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABT’s FA Score shows that 2 FA rating(s) are green whileMDT’s FA Score has 1 green FA rating(s), and SYK’s FA Score reflects 1 green FA rating(s).
- ABT’s FA Score: 2 green, 3 red.
- MDT’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABT’s TA Score shows that 5 TA indicator(s) are bullish while MDT’s TA Score has 7 bullish TA indicator(s), and SYK’s TA Score reflects 6 bullish TA indicator(s).
- ABT’s TA Score: 5 bullish, 3 bearish.
- MDT’s TA Score: 7 bullish, 3 bearish.
- SYK’s TA Score: 6 bullish, 4 bearish.
Price Growth
ABT (@Medical/Nursing Services) experienced а -1.54% price change this week, while MDT (@Medical/Nursing Services) price change was +0.82% , and SYK (@Medical/Nursing Services) price fluctuated +0.99% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.20%. For the same industry, the average monthly price growth was -0.54%, and the average quarterly price growth was -16.57%.
Reported Earning Dates
ABT is expected to report earnings on Jul 16, 2026.
MDT is expected to report earnings on Aug 25, 2026.
SYK is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.20% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| ABT | MDT | SYK | |
| Capitalization | 164B | 107B | 126B |
| EBITDA | 11.8B | 9.81B | 6.44B |
| Gain YTD | -24.177 | -11.183 | -5.666 |
| P/E Ratio | 26.31 | 22.49 | 38.17 |
| Revenue | 45.1B | 36.4B | 25.3B |
| Total Cash | 7.3B | 9.22B | N/A |
| Total Debt | 34B | 28B | 14.7B |
ABT | MDT | SYK | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 3 Undervalued | 10 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 59 | |
SMR RATING 1..100 | 64 | 72 | 57 | |
PRICE GROWTH RATING 1..100 | 61 | 57 | 57 | |
P/E GROWTH RATING 1..100 | 18 | 60 | 80 | |
SEASONALITY SCORE 1..100 | 50 | 65 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MDT's Valuation (3) in the Medical Specialties industry is in the same range as ABT (4) and is in the same range as SYK (10). This means that MDT's stock grew similarly to ABT’s and similarly to SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (59) in the Medical Specialties industry is somewhat better than the same rating for MDT (100) and is somewhat better than the same rating for ABT (100). This means that SYK's stock grew somewhat faster than MDT’s and somewhat faster than ABT’s over the last 12 months.
SYK's SMR Rating (57) in the Medical Specialties industry is in the same range as ABT (64) and is in the same range as MDT (72). This means that SYK's stock grew similarly to ABT’s and similarly to MDT’s over the last 12 months.
SYK's Price Growth Rating (57) in the Medical Specialties industry is in the same range as MDT (57) and is in the same range as ABT (61). This means that SYK's stock grew similarly to MDT’s and similarly to ABT’s over the last 12 months.
ABT's P/E Growth Rating (18) in the Medical Specialties industry is somewhat better than the same rating for MDT (60) and is somewhat better than the same rating for SYK (80). This means that ABT's stock grew somewhat faster than MDT’s and somewhat faster than SYK’s over the last 12 months.
| ABT | MDT | SYK | |
|---|---|---|---|
| RSI ODDS (%) | N/A | 6 days ago 57% | 3 days ago 54% |
| Stochastic ODDS (%) | 3 days ago 51% | 3 days ago 44% | 3 days ago 51% |
| Momentum ODDS (%) | 3 days ago 51% | 3 days ago 60% | 3 days ago 55% |
| MACD ODDS (%) | N/A | 6 days ago 48% | 4 days ago 49% |
| TrendWeek ODDS (%) | 3 days ago 54% | 3 days ago 52% | 3 days ago 54% |
| TrendMonth ODDS (%) | 3 days ago 47% | 3 days ago 45% | 3 days ago 47% |
| Advances ODDS (%) | 6 days ago 54% | 3 days ago 52% | 3 days ago 56% |
| Declines ODDS (%) | 3 days ago 54% | 13 days ago 57% | 12 days ago 53% |
| BollingerBands ODDS (%) | 3 days ago 57% | 3 days ago 43% | 3 days ago 47% |
| Aroon ODDS (%) | 3 days ago 45% | 3 days ago 32% | 3 days ago 45% |
Advertisement
ABT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABT has been loosely correlated with MDT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ABT jumps, then MDT could also see price increases.
MDT and
Correlation & Price change
A.I.dvisor indicates that over the last year, MDT has been loosely correlated with SYK. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if MDT jumps, then SYK could also see price increases.
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.